Business Description
Molecular Partners AG is a Swiss biotechnology company founded in 2004 and based in Schlieren, focused on developing a proprietary class of protein-based drugs known as DARPins to treat cancer. The company has several candidates in clinical trials targeting conditions such as advanced solid tumors, acute myeloid leukemia, and small cell lung cancer, among others. Its pipeline also includes an innovative platform for delivering radioactive payloads directly to tumor cells, with research partnerships in place with Orano Med SAS and Eckert & Ziegler SE to advance this approach.
